###begin article-title 0
The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 57 92 57 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">catechol-O-methyltranferase (COMT) </italic>
###xml 258 286 258 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apolipoprotein E gene (APOE)</italic>
The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE).
###end p 3
###begin p 4
###xml 19 27 <span type="species:ncbi:9606">patients</span>
A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and neuropsychological tests were used to establish diagnostic groups.
###end p 4
###begin p 5
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT Val158 Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively. Multinomial logistic regression models were used to determine the risk of AD and MCI.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 153 167 153 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;4 </italic>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 341 346 <span type="species:ncbi:9606">women</span>
Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The high activity genotypes (GG and AG) showed a synergistic effect with APOE epsilon4 allele, increasing the risk of AD (OR = 5.96, 95%CI 2.74-12.94, p < 0.001 and OR = 6.71, 95%CI 3.36-13.41, p < 0.001 respectivily). In AD patients this effect was greater in women.
###end p 7
###begin p 8
###xml 73 87 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;4 </italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 151 154 <span type="species:ncbi:9606">men</span>
In MCI patients such as synergistic effect was only found between AG and APOE epsilon4 allele (OR = 3.21 95%CI 1.56-6.63, p = 0.02) and was greater in men (OR = 5.88 95%CI 1.69-20.42, p < 0.01).
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 116 130 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;4 </italic>
###xml 160 165 <span type="species:ncbi:9606">women</span>
COMT (Val158 Met) polymorphism is not an independent risk factor for AD or MCI, but shows a synergistic effect with APOE epsilon4 allele that proves greater in women with AD.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 174 175 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 191 196 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 338 343 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 431 436 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 473 474 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Genetic, metabolic and environmental factors play a role in Alzheimer's disease (AD). The APOE epsilon4 allele is the strongest genetic risk factor for sporadic forms of AD [1]. However, the APOE gene explains only a fraction of the genetic risk associated with AD, and it is possible that other genes or metabolic factors may modify the APOE epsilon4 effect to initiate the pathogenesis of AD. One of these candidate genes is the COMT (Catechol-O methyltransferase) gene [2].
###end p 12
###begin p 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
COMT is located on chromosome 22. It has 6 exons, spans 27 kb and encodes a protein of 271 amino acids. There is a single functional nucleotide polymorphism (SNP) on exon 4 of the COMT gene: rs4680. This SNP is characterised by low allele A activity (ATG/methionine) and a (high activity) allele G (GTG/valine) in codon 158. O-methylation mediation by COMT is an important mechanism for inactivating estrogen. In contrast to the G (high activity) allele, the A (low activity) allele causes the accumulation of catecholestrogens [3].
###end p 13
###begin p 14
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE-</italic>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 555 556 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 720 721 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
###xml 613 616 <span type="species:ncbi:10116">rat</span>
In the last few years it has been suggested that estrogens could be implicated in the etiology of AD through a APOE-dependent mechanism. Estrogen effects upon the central nervous system (CNS) are modulated via the estrogen receptors and metabolites. In mice, estradiol promotes synaptic sprouting in response to an entorhinal cortex lesion model of AD via an APOE-dependent mechanism [4]. Other evidences from animal studies also indicates that 17-beta-estradiol exerts a strong protective effect by reducing neuronal apoptosis and inflammatory reponses [5]. 17-beta-estradiol activates protein kinase C (PKC) in rat neuron cultures, and this activation is an important step in estrogen protection against beta-amyloid [6].
###end p 14
###begin p 15
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 271 276 <span type="species:ncbi:9606">women</span>
The important decrease in endogenous estrogens levels after menopause may contribute to the development of AD [7]. Data from population-based studies support the hypothesis that estrogen replacement therapy is associated with a reduced prevalence of AD in postmenopausal women [8,9]. These data suggest a protective effect of estrogens upon AD.
###end p 15
###begin p 16
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT</italic>
Therefore, it is probable that genes such as COMT, involved in estrogen metabolism are associated with a greater likelihood of developing AD, and constitute genetic risk markers.
###end p 16
###begin p 17
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 261 263 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 283 285 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 308 313 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
Several studies have examined the relationships between COMT polymorphisms and the risk of sporadic AD. Wang et al. (2005) [10] found that COMT GG genotype and APOE epsilon4 allele to exert a synergistic effect upon the risk of AD. In addition, Borroni et al. [11] and Sweet et al. [12] have determined that COMT genetic variation was associated with a risk of psychosis in AD.
###end p 17
###begin p 18
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 502 504 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
The aim of the present study was to determine whether COMT is linked to the risk of AD; whether there is an interaction with APOE; and whether such interaction could influence the risk of AD. Our hypothesis is that the effect of COMT activity on estrogen levels may exist only between high activity alleles of COMT (G alleles) and epsilon4 status carriers. Accordingly, we have studied this effect in AD patients and in MCI patients, the latter condition possibly representing a prodrome for dementia [13].
###end p 18
###begin p 19
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT</italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
With the purpose of examining the influence of COMT, a gene involved in estrogen metabolism, as a genetic risk factor for cognitive impairment, we conducted a study of a sample of patients with mild cognitive impairment (MCI), Alzheimer's disease (AD) and a control group. All subjets were analyzed for COMT valine/methionine (rs4680) polymorphism and APOE genotype.
###end p 19
###begin title 20
Methods
###end title 20
###begin p 21
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 228 240 <span type="species:ncbi:9606">Participants</span>
This cross-sectional study comprised three subjects groups: MCI patients (n = 223), AD patients (n = 345) and healthy controls (n = 253). Subjets were prospectively recruited from the Neurology Departments of several hospitals. Participants were aged 50 years and older.
###end p 21
###begin p 22
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 562 565 562 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12 </sub>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
The subjects were evaluated using a broad battery of neuropsychological tests: Minimental State Examination (MMSE), Clinical Dementia Rating scale (CDR), CERAD protocol, Stroop test, unilateral and bilateral motor praxis, 7-minute test, trial making part A and B; and Neuropsychiatric Inventory (NPI). Clinical criteria for dementia and AD (DSM IV and NINCDS-ADRDA) [14,15] and Petersen's criteria for MCI, were used [13,16]. For AD and MCI patients, evaluation also included routine blood tests: haematology, biochemistry, thyroid-stimulating hormone, vitamin B12 levels, syphilis serology and neuroimaging test (CT scan or MRI).
###end p 22
###begin p 23
###xml 49 61 <span type="species:ncbi:9606">participants</span>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Based upon the results of these evaluations, the participants were classified into the following groups: MCI patients, AD patients, and healthy control subjects.
###end p 23
###begin p 24
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
A specific database was designed using Microsoft Access 2002 and declared to the Spanish Data Protection Agency. The study was approved by the Ethics Committee of Cruces Hospital. All patients signed informed consent to undergo the examination. The study was conducted in accordance with the Declaration of Helsinki concerning medical research in human subjects.
###end p 24
###begin title 25
###xml 4 12 <span type="species:ncbi:9606">patients</span>
MCI patients
###end title 25
###begin p 26
###xml 48 56 <span type="species:ncbi:9606">Patients</span>
The diagnosis was based on Petersen's criteria. Patients had memory complaints corroborated by an informant, representing a decline from a previous level of functioning given their age and educational level. The score in CDR scale was required to be 0.5, and performance in relation to other cognitive functions and daily living activities were required to be normal.
###end p 26
###begin title 27
###xml 3 11 <span type="species:ncbi:9606">patients</span>
AD patients
###end title 27
###begin p 28
###xml 45 47 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 110 118 <span type="species:ncbi:9606">Patients</span>
The diagnosis of AD was based on the DSM IV [14] and NINCDS-ADRDA [15] criteria for probable and possible AD. Patients with a total score of less than 3 on CDR scale (mild to moderate dementia) were included.
###end p 28
###begin title 29
Healthy control subjects
###end title 29
###begin p 30
These subjects scored within the normal ranges for age and educational level in psychometric testing, with a CDR score of 0.
###end p 30
###begin p 31
The exclusion criteria included: previous cerebrovascular diseases (transient ischemic attacks, stroke or intracranial haemorrhage), other neurodegenerative diseases, severe comorbidities making adequate follow-up unlikely, acute psychiatric diseases, and the absence of a reliable informant.
###end p 31
###begin title 32
Genetic analysis
###end title 32
###begin p 33
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
On the first visit, peripherical blood samples were collected at EDTA vacuum tubes from all individuals. Genomic DNA was extracted from white blood cells using standard phenol/chloroform extraction method. Then COMT Val158 Met (rs4680) and APOE genotypes were analyzed blinded to clinical diagnosis.
###end p 33
###begin p 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae </italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Afl </italic>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
APOE was amplified by PCR with the primers 112F and 158R, under the PCR conditions described by Wilton and Lim [17]. Digestion of the amplified product was carried out with Hae II and Afl III, as described by Alvarez-Alvarez et al. [18]. COMT genotyping was done using 5'-nuclease allelic discrimination assay on the ABI Prism 7000 Sequence Detection System. Taqman SNP genotyping products and Custom Taqman SNP Genotyping Assays were used. Reactions were done with the following protocol: 95degreesC for 10 min, 45 cycles at 95degreesC for 15 sec, and 58degreesC for 1 min 30 sec.
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Genepop software version 4.0 was used to calculate genotypic and allelic frequencies and to test the goodness of fit of patients and control samples to Hardy-Weinberg equilibrium by means of the exact test of Guo and Thompson [19].
###end p 36
###begin p 37
###xml 54 58 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 317 331 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE &#949;4 </italic>
###xml 387 392 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
Statistical analysis was also performed using the SPSS(R) package, version 15.0. Differences among demographic and clinical variables were evaluated using the chi- squared test and analysis of variance (ANOVA). A dichotomous variable was used for each polymorphism: "yes" or "no" for "carrier" or "no carrier" of the APOE epsilon4 allele and for different alleles and genotypes from the COMT gene.
###end p 37
###begin p 38
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 273 278 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 367 372 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 578 583 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
A multinonial regression model was created in order to determine the independent effect of any COMT allele and genotypes in the absence of epsilon4 allele; and the effect of epsilon4 allele in the total sample and a sample selected by at least one epsilon4 allele and no G COMT allele. Another model was created to evaluate the combined effect of epsilon4 allele and COMT genotypes, based on the hypothesis that the effect of estrogens might exists only in epsilon4 carriers. In all these models the reference categories were controls, females and the absence of epsilon4 and G COMT allele. P-values of less than 0.05 were considered statistically significant.
###end p 38
###begin title 39
Results
###end title 39
###begin p 40
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
We have investigated the independent and combined association of COMT Met108/158Val and APOE using a case-control design.
###end p 40
###begin p 41
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
In the present study we analyzed a sample of 223 MCI patients, 345 AD patients, and 253 healthy control subjects without significant differences in terms of age (p > 0.05).
###end p 41
###begin p 42
###xml 136 137 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
The MMSE scores for MCI, AD patients and controls were 26.58 +/- 2.16, 19.72 +/- 4.80 and 28.23 +/- 1.73 respectively (p < 0.05) (Table 1).
###end p 42
###begin p 43
Baseline demographics.
###end p 43
###begin p 44
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 43 45 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 66 68 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 50 55 <span type="species:ncbi:9606">women</span>
a Years, mean +/- standard deviation (SD). b % of women in group. c MMSE score, mean +/- standard deviation.
###end p 44
###begin p 45
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Table 2 shows the allele and genotype frequencies of COMT and APOE genes in MCI, AD and controls. In all studied groups, the COMT genotype frequencies were in Hardy-Weinberg equilibrium (p > 0.05). There were no significant differences in allele and genotype frequencies in MCI and AD compared to controls for COMT gene, while the differences proved significant for APOE gene (Table 3).
###end p 45
###begin p 46
Allele and genotype frequency.
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
aMCI: mild cognitive impairment. bAD: Alzheimer's disease. cHardy-Weinberg probability test.
###end p 47
###begin p 48
Exact G test, allele and genotype frequencies.
###end p 48
###begin p 49
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
a Allele frequency. bGenotype frequency. c Standard error.
###end p 49
###begin p 50
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
In order to determine whether COMT G allele is an independent risk factor for MCI and AD, we selected a subgroup of MCI, AD and control individuals with the presence of at least one COMT G (high activity) allele and the absence of APOE epsilon4 allele.
###end p 50
###begin p 51
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
The odds ratios (ORs) of developing MCI and AD were 0.90 (95%CI 0.53-1.51, p < 0.68) and 1.24 (95%CI 0.74-2.08, p = 0.42), respectively (Table 4). In subsequent analyses we obtained that any COMT genotype with at least one high activity allele (G) had a significative effect (data not shown).
###end p 51
###begin p 52
Risk factors for MCI and AD. Logistic regression models.
###end p 52
###begin p 53
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 106 108 106 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b1 </sup>
###xml 244 247 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b2 </sup>
###xml 315 317 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b3</sup>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 415 417 415 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 456 461 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
a Sample selected by at least one COMT genotype and absence of E4. Reference category was sample control. b Total sample with any exclusion, control sample was reference. b1 Total sample with any exclusion, female control sample was reference. b2 Total sample with any exclusion, male control sample was reference. b3Sample selected by at least one E4 and none COMT G allele. Reference category was sample control. c Sample selected by at least one E4 and COMT genotype. d Sample selected by at least one E4, COMT genotype and gender. *In all cases, reference category was control sample.
###end p 53
###begin p 54
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 220 225 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 297 302 <span type="species:ncbi:9606">women</span>
###xml 352 357 <span type="species:ncbi:9606">women</span>
###xml 404 407 <span type="species:ncbi:9606">men</span>
###xml 456 459 <span type="species:ncbi:9606">men</span>
APOE epsilon4 allele is a risk factor for cognitive impairment, and this risk is lower in MCI (OR = 2.53, 95%CI 1.69-3.79 p < 0.001) than in AD (OR = 4.37, 95%CI 3.02-6.33 p < 0.001). The higher risk conferred by allele APOE epsilon4 was observed even when the samples were subgrouped by sex: MCI women (OR = 2.46, 95%CI 1.45-4.15 p < 0.001) versus AD women (OR = 5.10, 95%CI 3.20-8.13 p < 0.01) and MCI men (OR = 2.59, 95%CI 1.36-4.92 p < 0.04) versus AD men (OR = 3.19, 95%CI 1.72-5.91 p < 0.001).
###end p 54
###begin p 55
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 157 162 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 197 202 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 413 418 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
Aiming to avoid the combined effect of COMT genotypes and allele APOE epsilon4, we analyzed the risk of MCI and AD according to the presence of at least one APOE allele epsilon4 and the absence of COMT G allele. The OR for MCI and AD were OR = 1.64, 95%CI 0.80-3.36, p = 0.18, and OR = 2.61, 95%CI 1.31-5.18, p < 0.01 respectively. These results could indicate a synergistic interaction between APOE epsilon4 and COMT G in MCI and AD patients.
###end p 55
###begin p 56
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
We further evaluated a possible synergistic effect between COMT and APOE by using a multivariate logistic regression model. To this effect, we subgrouped the subjets according to the high activity genotypes of COMT (GG or AG) and the presence of at least one APOE epsilon4 allele.
###end p 56
###begin p 57
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 226 231 <span type="species:ncbi:9606">women</span>
A synergistic effect between genotypes GG and AG with APOE epsilon4 was observed in AD patients (OR = 5.96, 95%CI 2.74-12.94, p < 0.001 and OR = 6.71 95%CI 3.36-13.41, p < 0.001 respectively). This effect is most notorious is women for both genotypes GG and AG (OR = 11.50, 95%CI 3.83-34.53, p < 0.001 and OR = 7.94 (95%CI 3.24-19.42, p < 0.01 respectively).
###end p 57
###begin p 58
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 192 193 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 142 145 <span type="species:ncbi:9606">men</span>
In MCI patients, this synergistic effect was only found between AG and APOE epsilon4 (OR = 3.21 95%CI 1.56-6.63, p = 0.02) and was greater in men (OR = 5.88 95%CI 1.69-20.42, p < 0,01) (Table 4).
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 275 280 <span type="species:ncbi:9606">women</span>
Our study shows that neither COMT alleles nor genotypes are independently associated with the risk of AD or MCI, but confirms an association between high activity alleles of COMT (G alleles), epsilon4 status carriers and the risk of AD. This effect is moreover greater in AD women.
###end p 60
###begin p 61
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 140 145 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 254 259 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 293 298 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 129 134 <span type="species:ncbi:9606">women</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
In our series, APOE epsilon4 allele is seen to be an independent risk factor for the AD population, and this risk is highest for women. The APOE epsilon4 allele also constitutes a risk factor for MCI patients. On evaluating the independent effect of the APOE epsilon4 allele in the absence of COMT genotype G, the risk for AD remains; though the association with the risk of MCI is lost.
###end p 61
###begin p 62
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 170 175 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 291 296 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 250 255 <span type="species:ncbi:9606">women</span>
###xml 354 357 <span type="species:ncbi:9606">men</span>
We have found the GG and AG genotypes to exert a synergetic effect with APOE epsilon4. When these genotypes are included into the multinomial analysis, the risk of AD in APOE epsilon4 allele and GG or AG carriers increases, and is more pronounced in women. The risk for MCI is only found in APOE epsilon4 allele and AG carriers, and is more notorious in men.
###end p 62
###begin p 63
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
To our knowledge, only two previous studies have evaluated the role of COMT polymorphism as a risk factor for AD [10,20]. The first study was conducted in Colombia by Forero et al. [20], and an initial association between AA low activity genotype and the risk of AD males (OR = 2.76, 95%CI 1.08-7.08, p = 0.02) was found. However, these associations were lost after Bonferroni correction for multiple testing.
###end p 63
###begin p 64
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 319 324 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 591 596 <span type="species:ncbi:9606">women</span>
Our findings are in accordance with the second study performed by Wang et al. [10]. These authors established that the GG genotype (COMT HH) and the presence of at least one APOE epsilon4 allele exerted a synergetic effect, increasing the risk of AD to 3.6 (95%CI 1.2 - 10.6). They postulated that the existence of the COMT HH genotype is a important modulating factor for the increased risk of developing AD. The sample size of our study allows a stratification by sex. In our series, similar ranges of values have been obtained for the most high activity genotypes (AG and GG), and mainly women with AD
###end p 64
###begin p 65
###xml 132 133 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 150 152 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 169 174 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 379 384 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 503 505 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 512 517 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 641 643 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 655 660 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 714 719 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 835 837 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 852 857 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 1038 1040 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
There is considerable evidence suggesting that allele epsilon4 constitutes a major susceptibility factor for the development of AD [1]. Some authors [21] have shown the APOE epsilon4 allele to be associated with an increased risk of MCI (OR: 6.04, 95%CI: 2.76-3.23; p < 0.001), though with no effect upon the probability of evolving AD. Despite the fact that the presence of the APOE epsilon4 allele has been associated with an increased risk of conversion from MCI to AD, the sensitivity is quite low [22]. The APOE epsilon4 allele is an important risk factor for AD, and may be useful for predicting who is likely to progress to dementia [23]. However, APOE epsilon4 carriers do not always develop dementia, and APOE epsilon4 carrier status in itself was not found to be predictive of cognitive decline or conversion to AD from MCI [24]. The role of APOE in brain repair mechanisms might be associated with the risk for AD, the epsilon4 allele being less effective in synaptic remodeling, repair, and regeneration after brain injuries [25].
###end p 65
###begin p 66
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 346 350 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 375 377 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 471 473 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 119 124 <span type="species:ncbi:9606">women</span>
###xml 149 152 <span type="species:ncbi:9606">men</span>
###xml 286 291 <span type="species:ncbi:9606">women</span>
###xml 464 469 <span type="species:ncbi:9606">women</span>
Several studies have shown an interaction between estrogen and APOE. Sex-specific incidence rates for AD are higher in women after menopause than in men [26], probably due to lack of estrogens, and the APOE epsilon4 allele is associated with a greater decline in cognitive functions in women. This finding may be supportive of sex differences in APOE-associated risk for AD [27]. Estrogen use was associated with a lesser cognitive decline among epsilon4-negative women [28].
###end p 66
###begin p 67
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 627 629 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 632 637 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 766 767 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 796 801 793 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 233 238 <span type="species:ncbi:9606">women</span>
The biological mechanisms underlying the effect of COMT gene upon the risk of AD fall beyond the scope of the present study, though different hypotheses could be postulated based on the literature. Worda et al. 2003 [29] showed that women with an high activity genotype (GG) present lower serum estrogen concentration. Therefore, this genotype could be correlated to a lesser neuroprotective effect, and differences in COMT genotype might be involved in causing variable effects of estrogens upon diseases. 17-beta-estradiol is metabolized via two major pathways: 16-alpha-hydroxilation or the formation of cathecholestrogens [30]. COMT enzyme participates in the metabolism of estrogens after their hydroxylation to catecholestrogens by forming O-methyl derivates [3]. Thus, polymorphism in the COMT gene affecting the activity of the enzyme could alter the levels of cathecolestrogens and consequently the estrogen neuroprotective effect.
###end p 67
###begin p 68
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
The ways in which COMT overactivity may interact with APOE epsilon4 comprise the lowering of brain estrogen levels.
###end p 68
###begin p 69
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 397 399 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
Tau hyperphosphorylation is proposed to be an early event characteristic of AD and other neurodegenerative diseases [31]. The neurofibrillary tangles present in AD consist mainly of hyperphosphorylated microtubule-associated protein tau [32]. 17 beta-estradiol exerts a neuroprotective effect through the inactivation of GSK-3beta, which is the kinase most implicated in tau hiperphosphorylation [33].
###end p 69
###begin p 70
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 388 390 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 435 437 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 459 464 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 628 633 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 801 803 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Another possible mechanism of action of estrogen is related to oxidative stress. Eichi et al. [34] demonstrated that catecholestrogens were catechol metabolites of 17-beta estradiol that induced DNA adducts. Oxidative damage may be an early event in the pathogenesis of AD when the balance between free radical generation and antioxidant capacities shifts toward free radical production [35]. This fact is already evident in early AD [36]. Finally, excessive COMT activity may induce saturation of methylation capacity, deficient methylation capacity having been linked to neurodegeneration. The metabolism of levodopa down the COMT pathway has been speculated to result in the saturation of cellular methylation capacity in Parkinson's disease (PD) and in accelerated cognitive decline and dementia [37].
###end p 70
###begin p 71
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 265 270 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 307 309 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 312 317 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 478 480 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
The distinction between APOE epsilon4 carriers and non-carriers in AD and MCI appears to be increasing in importance: in MCI, the risk of cognitive decline and progression to AD seems to be greatest in individuals who carry at least one copy of both the BCHE-K and APOE epsilon4 alleles. In a recent paper [37], APOE epsilon4 and butyrylcholinesterase-K (BuChE-K) were associated with an increased risk for cognitive decline in patients with Parkinson's Disease Dementia (PDD) [38]
###end p 71
###begin p 72
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Pharmacogenomics and the study of interindividual genetic variability, which plays a significant role in defining drug response and toxicity, could exert a potential influence upon the design of more efficacious and safe treatments. Rosiglitazone [39] and passive antibodies targeted to beta-amyloid peptide [40] have elicited treatment response in non-epsilon4 carriers with mild to moderate AD.
###end p 72
###begin p 73
###xml 803 808 803 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 716 719 <span type="species:ncbi:9606">men</span>
###xml 725 730 <span type="species:ncbi:9606">women</span>
Some limitations to our study must be adressed. The main limitation is that the study population comes from the hospital setting. A community-based study could provide more information. The serum leves of estradiol have not been measured, and we do not know whether the patients received estrogen replacement therapy in the last years. We also include a sample of patients with MCI, which is probably a heterogeneous clinical entity. Not all the subjects in this group develop AD, and some of them return to a normal cognitive status. More operational criteria for this clinical entity are nedeed. Such a lack of operational criteria could explain our discordant results in this particular population (more risk for men than women). Accordingly, prospective studies might elucidate not only the role of COMT genotypes in AD, but also in the evolution of cognitive impairment from the early stages.
###end p 73
###begin p 74
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
Our study also may be biased by the fact that the recruited MCI subjects could be in different stages of the disease, and individuals with a increased COMT activity genotype and APOE epsilon4 carrier status can convert more rapidly to AD, such individuals being under-represented in the MCI sample. This may explain the lower risk associated with the GG versus the AG genotype in MCI epsilon4 carriers.
###end p 74
###begin p 75
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 146 153 <span type="species:ncbi:9606">patient</span>
The strengths of our study are its multicenter nature including AD patients, healthy controls, and for the first time MCI patients. Moreover, the patient sample is not small, and the number of cases allows gender stratification.
###end p 75
###begin p 76
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 436 441 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 627 632 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 801 806 795 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 746 751 <span type="species:ncbi:9606">women</span>
The activity of the main enzymes implicated in acetylcholine metabolims (acetylcholine esterase and choline acetyltranferase) is affected by estrogen administration [41,42]. Based on this interaction between APOE and COMT genotypes, it could be possible to identify responder patients, that could derive more benefit from acetylcholinesterase inhibitors, actually the main treatment for AD. If the interaction between APOE epsilon4 and COMT genotypes in patients with AD is confirmed by future studies, new drugs could be developed to treat AD by regulating synaptic dysfunction and estrogen metabolism. Treatments that reduce COMT activity might prove useful in the treatment of AD or in preventing the progression from MCI to AD, especially in women. Elucidation of the mechanisms whereby increased COMT activity influences neurodegenerative processes in epsilon4 carriers might help clarify etiological mechanisms in AD.
###end p 76
###begin title 77
Conclusion
###end title 77
###begin p 78
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 263 268 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE </italic>
###xml 177 182 <span type="species:ncbi:9606">women</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 297 300 <span type="species:ncbi:9606">men</span>
In conclusion, COMT (Val158 Met) polymorphism is not an independent risk factor for AD or MCI, but exerts a synergistic effect with the APOE epsilon4 allele which is greater in women with AD. In MCI patients, this synergistic effect was only found between AG and APOE epsilon4, and was greater in men.
###end p 78
###begin title 79
List of abbreviations
###end title 79
###begin p 80
###xml 31 52 31 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apolipoprotein E gene</italic>
###xml 60 92 60 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catechol-O-methyltranferase gene</italic>
AD: Alzheimer's disease; APOE: apolipoprotein E gene; COMT: Catechol-O-methyltranferase gene; MCI: Mild cognitive impairment of amnesic type.
###end p 80
###begin title 81
Competing interests
###end title 81
###begin p 82
The authors declare that they have no competing interests.
###end p 82
###begin title 83
Authors' contributions
###end title 83
###begin p 84
MFM: main investigator, conceived of the study, and participated in its design and coordination, and drafted the manuscript. XEM: co-investigator; participated in its design and coordination, and drafted the manuscript. JCF: co-investigator; participated in its design and coordination, and drafted the manuscript. LGA: co-investigator; participated in its design and coordination, and drafted the manuscript. JMUV: co-investigator; participated in its design and coordination. BIJ: co-investigator; participated in its design and coordination. MAGB: co-investigator; participated in its design and coordination. JML: co-investigator; participated in its design and coordination. MCGF: participated in genetic analysis. AMS: performed the battery of neuropsychological tests. RBG: performed the battery of neuropsychological tests. SIB: performed the battery of neuropsychological tests. NO: performed the battery of neuropsychological tests. MBA: performed the battery of neuropsychological tests. MCZ: performed the battery of neuropsychological tests. MMP: co-investigator; participated in its design and coordination, and drafted the manuscript. All authors read and approved the final manuscript.
###end p 84
###begin title 85
Acknowledgements
###end title 85
###begin p 86
This study was supported in part by grants from Federacion de Asociaciones de Familiares de Enfermos de Azheimer de Euskadi, Fondo de Investigacion Sanitaria del Instituto Carlos III (Madrid), Pfizer Foundation and Ayudas a la Investigacion de la Obra Social de la Caja Vital Kutxa.
###end p 86
###begin article-title 87
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
###end article-title 87
###begin article-title 88
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes
###end article-title 88
###begin article-title 89
Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk
###end article-title 89
###begin article-title 90
Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease
###end article-title 90
###begin article-title 91
Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia
###end article-title 91
###begin article-title 92
Estrogen activates protein kinase C in neurons: role in neuroprotection
###end article-title 92
###begin article-title 93
Estrogen and neurodegeneration
###end article-title 93
###begin article-title 94
Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
###end article-title 94
###begin article-title 95
A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging
###end article-title 95
###begin article-title 96
Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease
###end article-title 96
###begin article-title 97
Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease
###end article-title 97
###begin article-title 98
Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease
###end article-title 98
###begin article-title 99
Mild cognitive impairment clinical trials
###end article-title 99
###begin article-title 100
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
###end article-title 100
###begin article-title 101
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
###end article-title 101
###begin article-title 102
Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis
###end article-title 102
###begin article-title 103
###xml 95 103 <span type="species:ncbi:9606">patients</span>
5-Hydroxytryptamine 6 receptor (5-HT(6)) receptor and apolipoprotein E (ApoE) polymorphisms in patients with Alzheimer's disease in the Basque Country
###end article-title 103
###begin article-title 104
Performing the exact test of Hardy-Weinberg proportion for multiple alleles
###end article-title 104
###begin article-title 105
Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia
###end article-title 105
###begin article-title 106
APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease
###end article-title 106
###begin article-title 107
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment
###end article-title 107
###begin article-title 108
Predictive value of APOE genotyping in incipient Alzheimer's disease
###end article-title 108
###begin article-title 109
Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment
###end article-title 109
###begin article-title 110
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion
###end article-title 110
###begin article-title 111
Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging
###end article-title 111
###begin article-title 112
A gender difference in the association between APOE genotype and age-related cognitive decline
###end article-title 112
###begin article-title 113
Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction
###end article-title 113
###begin article-title 114
###xml 98 103 <span type="species:ncbi:9606">women</span>
Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women
###end article-title 114
###begin article-title 115
Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance
###end article-title 115
###begin article-title 116
The GSK3 beta signaling cascade and neurodegenerative disease
###end article-title 116
###begin article-title 117
Neurodegenerative tauopathies
###end article-title 117
###begin article-title 118
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration
###end article-title 118
###begin article-title 119
###xml 96 110 <span type="species:ncbi:10036">Syrian hamster</span>
The ability of four catechol estrogens of 17beta-estradiol and estrone to induce DNA adducts in Syrian hamster embryo fibroblasts
###end article-title 119
###begin article-title 120
Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease
###end article-title 120
###begin article-title 121
Evidence of increased oxidative damage in subjects with mild cognitive impairment
###end article-title 121
###begin article-title 122
BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline
###end article-title 122
###begin article-title 123
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
###end article-title 123
###begin article-title 124
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
###end article-title 124
###begin article-title 125
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
###end article-title 125
###begin article-title 126
###xml 70 73 <span type="species:ncbi:10116">rat</span>
Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area
###end article-title 126
###begin article-title 127
Age and sex-dependent decreases in ChAT in basal forebrain nuclei
###end article-title 127

